Sanofi to acquire Inhibrx for $1.7B - Endpoints News


1/23/2024

Sanofi to acquire Inhibrx for $1.7B  Endpoints NewsSanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal  STATSanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs  FierceBiotechInhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B  PR NewswireFrance's Sanofi boosts rare disease business with about $2.2 billion Inhibrx deal  Yahoo Finance...

Original

Tags: announces | billion | business | cancer | disease | drug | finance | news | rare | sale | u.s.



Let us know what you think!

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Leave a Comment

Scroll back to top